Clinical trial

Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT03443414

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-06-01

PhasePHASE2

Study timeline

Study start (actual)2017-06-01Date precision: day

Registry last updated2019-06-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

COPDunresolved

Interventions

RPL554 suspensionDRUG

PlaceboDRUG

Sponsors & collaborators

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAlead sponsor

Mapped research locations

SofiaBulgaria5 BerlinGermany4 WarsawPoland2 BucharestRomania2 KrakowPoland2 LodzPoland2 WroclawPoland2 BialystokPoland2 LeipzigGermany2 FrankfurtGermany2 HamburgGermany1 ManchesterUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03443414 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.